Black Diamond Therapeutics (BDTX) Operating Expenses (2018 - 2026)

Black Diamond Therapeutics (BDTX) has reported Operating Expenses for 9 consecutive years, with $12.1 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Operating Expenses fell 10.16% year-over-year to $12.1 million; the trailing twelve-month figure through Jun 2026 stood at $51.9 million (down 20.51% YoY), and the FY2025 full-year result was $57.5 million, down 27.04% from the prior year.
• Operating Expenses climbed to $12.1 million in Q2 2026 per BDTX's latest filing, from $11.3 million in the prior quarter.
• Across five years, Operating Expenses topped out at $25.7 million in Q1 2022 and bottomed at $11.0 million in Q3 2025.
• Historically, Operating Expenses has averaged $18.8 million across 5 years, with a median of $20.1 million in 2023.
• The sharpest annual moves came in 2024 and 2025: Operating Expenses grew 10.47% in 2024, then plunged 39.45% in 2025.
• Over 5 years, Operating Expenses stood at $21.9 million in 2022, then retreated by 4.56% to $20.9 million in 2023, then declined by 12.37% to $18.3 million in 2024, then retreated by 3.64% to $17.6 million in 2025, then slumped by 31.53% to $12.1 million in 2026.
• According to Business Quant data, Operating Expenses over the past three periods registered $12.1 million, $11.3 million, and $17.6 million for Q2 2026, Q1 2026, and Q4 2025 respectively.